ruxolitinib

Overview

Ruxolitinib is a selective, orally administered small-molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), two tyrosine kinases that play central roles in cytokine signaling through the JAK/STAT pathway. By blocking JAK1 and JAK2 activity, ruxolitinib suppresses downstream signaling through transcription factors such as STAT1 and STAT5A, thereby attenuating the aberrant cytokine-driven inflammation and cell proliferation that underlies several hematologic malignancies and immune-mediated disorders. It was among the first JAK inhibitors to receive regulatory approval and belongs to the broader class of Janus kinase inhibitors that has transformed the management of myeloproliferative neoplasms and inflammatory conditions.

Ruxolitinib is approved for the treatment of intermediate- or high-risk myelofibrosis (MF), polycythemia vera (PV) in patients who are resistant to or intolerant of hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease (GVHD). Its mechanism centers on the inhibition of constitutively active or mutant JAK2 (including JAK2 V617F), as well as JAK2 gain-of-function mutations, which drive pathological activation of the JAK2/STAT3 signaling pathway and CD44/JAK2/STAT3 signaling pathway in malignant hematopoietic cells. By dampening these cascades, ruxolitinib reduces splenomegaly, alleviates disease-related symptoms, and modulates immune responses relevant to both cancer and autoimmune disease contexts.

Recent Publications Summary

Recent clinical research has demonstrated ruxolitinib's efficacy across multiple hematologic malignancies and immune-mediated conditions. In steroid-refractory acute and chronic graft-versus-host disease (GVHD), long-term outcomes from 118 patients treated with ruxolitinib in a pre-approval named-patient program showed an overall response rate of 68.9% in acute GVHD 42560429Aug. Ruxolitinib has also been investigated for GVHD prevention in haploidentical hematopoietic stem-cell transplantation as part of a combinatorial regimen with anti-thymocyte globulin, calcineurin inhibitor, and short-course methotrexate, replacing mycophenolate mofetil with low-dose ruxolitinib 42532067Jul.

The JAK1/2 inhibitor has become standard first-line therapy for symptomatic myelofibrosis, with combination approaches showing enhanced efficacy. The phase 3 SENTRY trial demonstrated that selinexor, an exportin 1 inhibitor, combined with ruxolitinib achieved significantly higher spleen volume reduction (49.8% versus 28.0% at week 24) compared to placebo plus ruxolitinib in JAK inhibitor-naïve patients 42227656Jun. A phase 1 portion identified selinexor 60 mg as the recommended clinical dose with a manageable safety profile 41785311Mar. In a separate phase 2 study, the BCL-XL/BCL-2 inhibitor navitoclax was combined with ruxolitinib in JAK inhibitor-naïve myelofibrosis patients 41846295Mar. Real-world data have corroborated efficacy in related myeloproliferative conditions: a prospective German cohort of 433 patients with polycythemia vera demonstrated pronounced hematocrit reductions and leukocyte count improvements, particularly in JAK inhibitor-naïve patients 42118306May. High-dose ruxolitinib (25 mg twice daily) demonstrated feasibility and acceptable safety in a real-world myelofibrosis cohort 42081119May, and a longitudinal Japanese cohort study of 836 myelofibrosis patients characterized treatment patterns and outcomes in 281 patients receiving Janus kinase inhibitors 42102170May.

Beyond classic myeloproliferative neoplasms, ruxolitinib has shown therapeutic promise in diverse acute conditions. For intractable diarrhea following ciltacabtagene autoleucel CAR-T cell therapy in multiple myeloma, ruxolitinib led to rapid clinical improvement in three of five patients, with histopathologic evidence of response in matched biopsies 41592291Jan. Emapalumab, a monoclonal antibody targeting interferon-γ, was evaluated in combination with conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis 42397658Jul. A case report documented successful combination treatment of TAFRO-like syndrome with ruxolitinib and ropeginterferon alfa-2b, highlighting the JAK/STAT pathway's role in inflammatory disease 41161803Oct. Topical ruxolitinib (15 mg/g) in 100 patients with facial vitiligo showed significant improvements across clinical indices and quality-of-life measures when combined with noninvasive imaging evaluation 42473916Jul.

Mechanistic investigations have supported ruxolitinib's efficacy in disease-specific contexts. In B-cell precursor acute lymphoblastic leukemia with JAK2 gain-of-function mutations, ruxolitinib selectively reduced STAT5 phosphorylation, with distinct Raman spectral changes detectable in JAK2-mutant cells 41762803Feb. Immunologic profiling of steroid-refractory acute GVHD revealed expansion of CD28+ CD8+ effector-memory T cells associated with a STAT1-dependent glucocorticoid receptor deficit, providing mechanistic insights into resistance mechanisms 41980031Apr. Sequential therapy experience has also emerged: momelotinib, a JAK1/JAK2/ACVR1 inhibitor, demonstrated clinical benefit in patients with myelofibrosis after ruxolitinib failure in a real-world cooperative study 42118670May.

What Changes, What Holds

1. Ruxolitinib prevents GVHD in haploidentical transplantation
NEW DIRECTION Prevention of GVHD through incorporation into myeloablative conditioning 42532067Jul represents a clinical role not covered by the approved indication, which limits ruxolitinib to steroid-refractory disease treatment. While efficacy in the established treatment setting is reconfirmed, 42560429Aug extending into prophylaxis before GVHD develops opens a distinct therapeutic strategy with potentially different timing and patient selection implications.

2. Selinexor combined with ruxolitinib doubles spleen volume reduction in JAK inhibitor-naïve myelofibrosis
NEW DIRECTION Combination approaches integrating ruxolitinib with exportin-1 inhibitors 42227656Jun and BCL-2 family inhibitors extend therapeutic strategy beyond the monotherapy model described in the Overview. Enhanced responses in newly diagnosed patients suggest clinical practice may evolve toward multi-agent frontline regimens rather than ruxolitinib monotherapy as the standard approach.

3. Ruxolitinib succeeds topically for vitiligo and systemically for inflammatory syndromes beyond approved hematologic indications
NEW DIRECTION Topical ruxolitinib for vitiligo 42473916Jul and systemic uses including rapid improvement in CAR-T-associated diarrhea 41592291Jan establish therapeutic roles the Overview does not address. These applications recast ruxolitinib as a broadly applicable anti-inflammatory agent rather than a therapy confined to myeloproliferative neoplasms and steroid-refractory GVHD.

4. Immunologic resistance in steroid-refractory GVHD involves STAT1-dependent glucocorticoid receptor deficiency
NEW DIRECTION Profiling of treatment-resistant patients 41980031Apr reveals STAT1-linked glucocorticoid dysfunction not addressed by the Overview's description of JAK pathway suppression, explaining partial responses within an approved indication. Sequential therapy with alternative JAK inhibitors after ruxolitinib failure 42118670May indicates defined resistance patterns rather than universal efficacy in steroid-refractory GVHD.

Overview update candidates: combination selinexor-ruxolitinib in myelofibrosis with demonstrated superior efficacy to monotherapy may warrant updating first-line guidance.